Skip to main content

Latest news

Teva Canada announces availability of Aermony RespiClick™, an innovative new device for the treatme...

Teva Canada announces availability of Aermony RespiClick™, an innovative new device for the treatment of bronchial asthma

Teva Canada announces product availability of AJOVY™

Teva Canada announces product availability of AJOVY™

CGPA releases blueprint for a sustainable supply of prescription medicines for Canadians

CGPA releases blueprint for a sustainable supply of prescription medicines for Canadians

Teva Canada secures Salbutamol Inhalers from its global supply chain to mitigate shortage in Canadia...

Teva Canada secures Salbutamol Inhalers from its global supply chain to mitigate shortage in Canadian market

Availability of UK-Labelled Product – Salbutamol Metered Dose Inhaler (MDI)

Availability of UK-Labelled Product – Salbutamol Metered Dose Inhaler (MDI)

Importation of Teva UK-labelled Salamol CFC-Free (Salbutamol Sulfate) Inhaler due to shortage

Importation of Teva UK-labelled Salamol CFC-Free (Salbutamol Sulfate) Inhaler due to shortage

Teva Canada announces the launch of AJOVY™

Teva Canada announces the launch of AJOVY™

COVID-19 is increasing the number of Canadians requiring caregiver information and support

COVID-19 is increasing the number of Canadians requiring caregiver information and support

Teva 2018 Social Impact Report

Teva 2018 Social Impact Report

Recognizing the Caregiver‐Pharmacist Connection on National Caregiver Day

Recognizing the Caregiver‐Pharmacist Connection on National Caregiver Day

Teva Canada Innovation Announces Approval of Three-Times-a-Week COPAXONE® 40mg/mL by Health Canada

Teva Canada Innovation Announces Approval of Three-Times-a-Week COPAXONE® 40mg/mL by Health Canada

Teva Canada Innovation Announces Approval of CINQAIR™ by Health Canada

Teva Canada Innovation Announces Approval of CINQAIR™ by Health Canada